AAM Applauds HHS For Acknowledging Brand-Driven Cost Increases
Association Recommends Policy Solutions To Congress As Proposals To Lower Prices Unveiled
Executive Summary
The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”
You may also be interested in...
Fresenius Kabi To Build ‘One Of The Largest Sterile Injectable Manufacturing Networks In US’
Stating the importance of the US sterile injectables market for Fresenius Kabi, Matt Kuhn, senior director of external communications, talks to Generics Bulletin about the company’s plans to build one of the largest sterile injectable manufacturing networks in America. Meanwhile Ali Ahmed, senior vice president of biosimilars at Fresenius Kabi in the US, talks about supply reliability in biosimilars.
Biosimilars Forum Says 75% Market Share Could Save US Billions
The Biosimilars Forum, in partnership with the Pacific Research Institute, has released a report that shows state-by-state cost savings for the US if biosimilars were able to capture a market share of 75%. Meanwhile, the Association for Accessible Medicines has also released its complete 2021 US Generic And Biosimilar Medicines Savings Report, discouraging reducing incentives for patent challenges and early generic entry.
US Savings Top $338bn In 2020
Savings achieved in the US through the use of generics and biosimilars hit a new high in 2020, reaching $338bn, according to new figures released by the AAM.